How is a secretagogue different from taking GH?

It prompts the pituitary to release its own GH, so feedback regulation and pulsatility remain in the loop. Exogenous GH bypasses all of that.

Does that make secretagogues weaker?

It imposes a ceiling. A secretagogue can only release what the gland has and is prepared to release. That is both a limitation and a safety-relevant property.

Are they prohibited in sport?

Yes. WADA prohibits growth hormone secretagogues as a class.

What Is a Growth Hormone Secretagogue?

The short answer

A secretagogue is a compound that causes a gland to release something it already produces. Growth hormone secretagogues prompt the pituitary to release its own GH, which is a different intervention from administering exogenous growth hormone.

Key facts

Meaning: Prompts release of an endogenous substance
Target gland: Anterior pituitary
Two receptor routes: GHRHR and GHS-R1a
Retains: Physiological feedback regulation
Contrast: Exogenous GH bypasses the pituitary
WADA: Prohibited class in sport

The word itself

Secretagogue combines secretion with the Greek agogos, leading or drawing forth. It describes a compound that draws out a secretion rather than supplying the substance. The same logic applies elsewhere: an insulin secretagogue prompts the pancreas to release its own insulin rather than delivering insulin.

Why it differs from giving the hormone

Exogenous GH bypasses the pituitary entirely, and with it every regulatory mechanism the body normally applies: negative feedback from IGF-1, somatostatin tone, the pulsatile pattern. A secretagogue works through the gland, so those controls remain in the loop. Whichever direction the pituitary is regulating, it continues to regulate.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

The ceiling that implies

A secretagogue can only release what the pituitary has and is prepared to release. If the gland is depleted, or somatostatin tone is high, or feedback inhibition is active, the achievable response is limited in a way that injecting the hormone is not. That is a safety-relevant property and a limitation at the same time.

Two receptor routes

GH secretagogues divide by receptor. GHRH analogues such as CJC-1295 act at GHRHR. Ghrelin receptor agonists such as ipamorelin, and the earlier GHRP compounds, act at GHS-R1a. Both classes are secretagogues; they simply approach the same cell through different doors.

Regulatory status of the class

Growth hormone secretagogues are prohibited in sport under the World Anti-Doping Agency list, which applies to the class rather than to individual compounds. None of the compounds discussed here holds a marketing authorisation from the MHRA, EMA or FDA.

Frequently asked questions

How is a secretagogue different from taking GH?: It prompts the pituitary to release its own GH, so feedback regulation and pulsatility remain in the loop. Exogenous GH bypasses all of that.
Does that make secretagogues weaker?: It imposes a ceiling. A secretagogue can only release what the gland has and is prepared to release. That is both a limitation and a safety-relevant property.
Are they prohibited in sport?: Yes. WADA prohibits growth hormone secretagogues as a class.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
▸Ghrelin-receptor binding assays for Ipamorelin analogue development
▸Analytical HPLC method development for lipidated GHRH analogues
▸Stability testing under refrigerated storage

Handling checklist

✓Store lyophilised at −20 °C long-term
✓Reconstitute in bacteriostatic water; both peptides dissolve readily
✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum